All manuscripts must be submitted electronically to https://circinterventions-submit.aha-journals.org. Before proceeding to the online submission site, please prepare your manuscript according to the instructions below. Please also review the journal's Article Types page to ensure that your manuscript meets the criteria set forth for your submission type.
- Manuscripts should be typed double-spaced, including title page, abstract, text, references, figure legends, and tables. Leave a 1-inch margin on all sides.
- Author Service: The journal’s publisher, Wolters Kluwer, in partnership with Editage, offers a unique range of editorial services to help you prepare a submission-ready manuscript. For more information, please visit wkauthorservices.editage.com.
- Cite references, figures, and tables in numeric order.
- For manuscript review, a single PDF or Word document with the figures and tables embedded is preferred.
- Use SI units of measure. A more conventionally used measurement may follow in parentheses. Make all conversions before manuscript submission.
- Please provide sex-specific and/or race/ethnicity-specific data when appropriate in describing the outcomes of epidemiologic analyses or clinical trials, or specifically state that no sex-based or race/ethnicity-based differences were present.
- Consult the American Medical Association Manual of Style, 10th ed, New York, Oxford University Press, 2007, for style.
- Manuscripts must conform to the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” (http://www.icmje.org/).
- Assemble the manuscript in this order: Title Page, Abstract, Text, Acknowledgments, Sources of Funding, Disclosures, References, Figure Legends, Tables, and Figures.
The title page (page 1, do not number) should contain these elements:
- Full title
- First author’s surname and short title (not to exceed 50 characters, including spaces)
- Authors’ names, academic degrees, and affiliations
- Name and complete address for correspondence (include street name and address as well as post office box, and address for reprints if different from correspondence address)
- Fax number, telephone number, and email address
- The total word count of the manuscript, including the title page, abstract, text, references, tables, and figures legends
- Do not cite references in the abstract.
- Limit use of acronyms and abbreviations. Define at first use with acronym or abbreviation in parentheses.
- Maximum of 250 words
- Use the following headings:
- Background—rationale for study
- Methods and Results—brief presentation of methods and presentation of significant results; please include sample size
- Conclusions—succinct statement of data interpretation
- When applicable, include a fourth heading, "Clinical Trial Registration." Please list the URL, as well as the Unique Identifier, for the publicly accessible website on which the trial is registered.
- Typical main headings include Introduction, Methods, Results, and Discussion.
- Number pages and include line numbers restarting on each page.
- Abbreviations must be defined at first mention.
Please note that the print version of the Methods and Results should be able to stand alone and should provide sufficient information for the reader to understand the basic methods of the study and to review the fundamental findings in a mechanistic way.
- Experimental animals: State the species, strain, number used, and pertinent descriptive characteristics. When describing surgical procedures, identify the preanesthetic and anesthetic agents used and the amounts, concentrations, routes, and frequency of administration of each. Paralytic agents are not considered acceptable substitutes for anesthetics. For other invasive procedures on animals, report the analgesic or tranquilizing drug used. If none were used, provide justification for exclusion.
- Human studies: Indicate that the study was approved by an institutional review board along with the name of the IRB, and that the participants gave written informed consent (or that no informed consent was required).
- Studies of medications, biologics and devices: Generic rather than trademark names of all therapeutics should be used.
- Independent data access and analysis: The Editors consider it preferable for investigators to have direct access to the primary data from a clinical trial (raw and derived datasets) for analysis and reporting of trial results. Alternatively, a party or organization independent from the trial sponsor with access to the primary data may provide data analyses. It is recognized that for logistical reasons these options may not be possible in all instances. At a minimum, the authors should have the ability to query any aspect of the data either directly or through independent analysis. A specific comment in the paper is required attesting that one author had full access to all the data in the study and takes responsibility for its integrity and the data analysis. The Editors reserve the right to ask for additional information from the corresponding author regarding measures that were taken to minimize bias and verify the integrity of the primary data and any analyses performed.
- Transparency and Openness Promotion (TOP) Guidelines: Please ensure that your manuscript adheres to the AHA Journals' implementation of the TOP Guidelines (available online at http://www.ahajournals.org/content/TOP-guidelines).
- Research Guidelines: Additional information regarding research guidelines can be found at http://circinterventions.ahajournals.org/content/research-guidelines.
The corresponding author must sign the “Acknowledgment Section” of the Copyright Transfer Agreement, certifying that (1) persons who have made substantial contributions to the research and/or manuscript (e.g., study conduct, data collection, data analyses, writing or editing assistance), but who do not fulfill authorship criteria, are named with their specific contributions in the Acknowledgments section of the manuscript; and (2) all persons named in the Acknowledgments section have provided the corresponding author with permission to be named in the manuscript.
Sources of Funding
- All sources of support for the research should be listed under this heading.
- All grant funding agency abbreviations should be completely spelled out, with the exception of the NIH.
Each author must disclose all relevant financial, personal or professional relationships with other people or organizations. To protect the integrity of the author, Journal, and the AHA, disclosure must be made of both those relationships that pose a conflict and those that could reasonably be perceived as a conflict of interest or as potentially influencing or biasing the author's work. Authors' disclosures will appear after the "Acknowledgments" section in the accepted article.
A. Each author is required to identify all relationships within the last 2 years that are relevant to the topic of the manuscript. A relationship is "relevant" if the relationship or interest relates to the topic of the manuscript in terms of any of the following: the same or similar subject matter or topic; the same, similar or competing drug or device, product or service, intellectual property or asset; a drug or device company or its competitor; or has the reasonable potential to result in financial, professional or other personal gain or loss for you, members of your household or employer. Note these definitions of the categories: "Research Grant" includes principal investigator, collaborator or consultant and pending grants as well as grants already received. "Other Research Support" includes receipt of drugs, supplies, equipment or other in-kind support. "Honoraria" includes speaking fees for symposia and other meetings or occasions. "Expert Witness" includes serving as an expert witness, consultant or otherwise providing a deposition, testimony, or other information, analysis or document for a lawsuit, government agency proceeding, grand jury, or other legal proceeding, even if the case did not go to trial. "Ownership Interest" includes stock; stock options; partnership, membership, or other equity position in an entity regardless of the form of the entity, or any option or right to acquire such position; or any rights in any patent or other intellectual property. If an author has no relationships or conflicts to disclose, the author must indicate "None" for the appropriate category(ies).
B. Each author is required to classify each disclosed relationship as either "Significant" or "Modest".A relationship is considered to be "Significant" if (a) the person receives $10,000 or more during any 12 month period, or 5% or more of the person's gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10,000 or more of the fair market value of the entity.A relationship is considered to be "Modest" if it is less than "Significant" under the preceding definition.
Please state "None" if no conflicts exist.
- Users of EndNote can find the appropriate Output Style here. Please note that these do not always match our style and you may need to manually correct your references.
- Accuracy of reference data is the responsibility of the author.
- Verify all references against original sources.
- List all authors for each reference; do not use “et al.”
- Example of a good reference:
- Smith HJ, Allen S, Yu W, Fard S. This is the title. Circulation. 2004;104:276-308. doi: 10.1161/01.CIR.0000140263.20897.42.
- Cite references in numerical order according to first mention in the text. In the text, ensure accuracy of spelling and details of publication, i.e., the text citation should match the reference information.
- Personal communications, unpublished observations, and submitted manuscripts are not legitimate references. They must be cited in the text only (not in the reference list) as follows: author name, degree(s) held, unpublished data, year.
- References must be from a full-length publication in a peer-reviewed journal.
- Abstracts may be cited only if they are the sole source and must be identified in the reference as “Abstract.”
- “In press” citations must have been accepted for publication and the name of the journal or book publisher must be included.
- Figure parts should be clearly labeled. Letters and locants must be uniform in size and style within each figure, and when possible, between figures. (The font size must be 10 point or higher.)
- Avoid headings on the figure. Heading information should appear in the figure legend.
- Line art should not contain hair lines, which are hard to reproduce.
- Supply a scale bar with photomicrographs.
- Provide double-spaced copy for figure legends on a separate page.
- Symbols and abbreviations must be defined in the figure or its legend.
- Limit white space between the panel and panel label.
- Figures should be sized as close as possible to their final print size. Please note that very few figures qualify for a 2-column format.
- Begin each table on a separate page, double-spaced. Please remember that tables prepared with Excel are not accepted unless embedded within your text document.
- The table number should be Arabic, followed by a period and brief title.
- Use same size type as in text.
- Supply a brief heading for each column.
- Indicate footnotes in this order: *, †, ‡, §, ||, #, **.
- Abbreviations used in the table must be defined in a footnote to the table.
Data Supplements are encouraged as an enhancement to the Methods section. This optional section provides an opportunity to present supporting materials to the manuscript. Please note that all supplements undergo peer review and must be submitted with each iteration of the manuscript.
Data Supplements can consist of the following:
- Expanded Methods and Results
- Additional Figures
- Additional Tables
- Video Files
If citations are made in a Data Supplement, the supplement must contain its own Reference Section, with references numbered sequentially beginning with the number 1. Please try to keep the individual file size to 10 MB or less to facilitate easier downloading for readers.
A combined PDF of your supplemental data must be provided. The first page of this PDF should include the heading "SUPPLEMENTAL MATERIAL." Please note that this single PDF would include all of the supplemental material related to your manuscript, except for the Video or Movie files. The supplemental material to be included in this PDF is as follows: Supplemental Methods, Supplemental Tables, Supplemental Figures and Figure Legends, and Supplemental References. The legends for any Video files should also be included in this PDF.
Supplemental Materials Required for Review
- A copy of all submitted manuscripts related to the present submission must be submitted as part of the review process.
- A copy of all manuscripts, either in preparation or submitted, that potentially overlap with your Circulation: Cardiovascular Interventions submission. Please note that failure to include such material is a violation of the journal's Ethics Policy.
- A copy of all “in press” articles cited in the Reference section must be supplied for review by the editors and the reviewers.